AR037083A1 - Metodos para la produccion de proteinas redox y complejos proteicos heteromultimericos; composiciones relacionadas - Google Patents
Metodos para la produccion de proteinas redox y complejos proteicos heteromultimericos; composiciones relacionadasInfo
- Publication number
- AR037083A1 AR037083A1 ARP010105914A ARP010105914A AR037083A1 AR 037083 A1 AR037083 A1 AR 037083A1 AR P010105914 A ARP010105914 A AR P010105914A AR P010105914 A ARP010105914 A AR P010105914A AR 037083 A1 AR037083 A1 AR 037083A1
- Authority
- AR
- Argentina
- Prior art keywords
- recombinant polypeptide
- fatty
- recombinant
- protein
- clause
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 32
- 108090000623 proteins and genes Proteins 0.000 title abstract 32
- 238000000034 method Methods 0.000 title abstract 15
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 43
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 43
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 43
- 150000007523 nucleic acids Chemical group 0.000 abstract 12
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 11
- 230000008685 targeting Effects 0.000 abstract 11
- 108060003951 Immunoglobulin Proteins 0.000 abstract 5
- 102000018358 immunoglobulin Human genes 0.000 abstract 5
- 101710089395 Oleosin Proteins 0.000 abstract 4
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 4
- 229930195729 fatty acid Natural products 0.000 abstract 4
- 239000000194 fatty acid Substances 0.000 abstract 4
- 150000004665 fatty acids Chemical class 0.000 abstract 4
- 235000013305 food Nutrition 0.000 abstract 4
- 102000002933 Thioredoxin Human genes 0.000 abstract 3
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 abstract 3
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 abstract 3
- 108060008226 thioredoxin Proteins 0.000 abstract 3
- 229940094937 thioredoxin Drugs 0.000 abstract 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 238000013518 transcription Methods 0.000 abstract 2
- 230000035897 transcription Effects 0.000 abstract 2
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 abstract 1
- 208000005374 Poisoning Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 101710120037 Toxin CcdB Proteins 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 abstract 1
- 230000005741 malignant process Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 231100000572 poisoning Toxicity 0.000 abstract 1
- 230000000607 poisoning effect Effects 0.000 abstract 1
- 231100000397 ulcer Toxicity 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
- C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Un método para producir un cuerpo graso asociado con un complejo proteico multimérico recombinante, comprendiendo dicho método los pasos de: a) producir en una célula que contiene cuerpos grasos, un primer polipéptido recombinante y un segundo polipéptido recombinante, donde dicho primer polipéptido recombinante tiene la capacidad de asociarse con dicho segundo polipéptido recombinante para formar dicho complejo proteico multimérico; y b) asociar dicho complejo proteico multimérico con un cuerpo graso por medio de una proteína direccionadora a cuerpos grasos capaz de asociarse con dicho cuerpo graso dicho primer polipéptido recombinante. El método contempla además el aislamiento de los cuerpos grasos asociados con dicho complejo proteico multimérico recombinante. Cada una de dichas proteínas direccionadoras a cuerpos grasos puede ser una proteína del cuerpo graso o una inmunoglobulina. La proteína direccionadora a cuerpos grasos es una oleosina o una caleosina. El primer polipéptido recombinante se puede fusionar a dicha oleosina o caleosina, de manera similar, se puede fusionar el segundo polipéptido recombinante a una segunda oleosina o una segunda caleosina capaz de asociarse con un cuerpo graso. El complejo proteico multimérico es un complejo redox enzimáticamente activo o una inmunoglobulina. Reivindicación 21: Un método para expresar un complejo proteico multimérico recombinante que comprende un primer y segundo polipéptido recombinante de una célula, comprendiendo dicho método los pasos de: a) introducir en una célula una primera secuencia de ácido nucleico quimérica que comprende: (i) una primera secuencia de ácido nucleico capaz de regular la transcripción de dicha célula ligada operativamente a; (ii) una segunda secuencia de ácido nucleico que codifica al primer polipéptido recombinante; b) introducir en dicha célula una segunda secuencia de ácido nucleico quimérica que comprende: (i) una tercera secuencia de ácido nucléico capaz de regular la transcripción en dicha celula ligada operativamente a; (ii) una cuarta secuencia de ácido nucléico que codifica un segundo polipéptido recombinante; © cultivar dicha célula bajo condicions que permitan la expresión de dicho primer y segundo polipéptido recombinante en una célula de la progenie que contenga cuerpos grasos, donde dicho primer polipéptido recombinante y dicho segundo polipéptido recombinante tiene la capacidad de formar un complejo proteico multimerico y (d) asociar dicho primer polipéptido recombinante con un cuerpo graso por medio de una proteína direccionadora a cuerpos grasos capaz de asociarse con dicho cuerpo graso y dicho primer polipéptido recombinante. Reivindicación 26: El método de la cláusula 25, donde cada una de dichas proteínas direccionadoras a cuerpos grasos se selecciona entre una proteína del cuerpo graso o una inmunoglobulina. Reivindicación 27: El método de la cláusula 26, donde dicha proteína del cuerpo graso es una oleosina o una caleosina. Reivindicación 35: El método de la cláusula 21, donde dicho primer polipéptido recombinante es una tioredoxina y dicho segundo polipéptido recombinante es una tioredoxina-reductasa. Reivindicación 38: El método acorde con la cláusula 21, donde dicho primer polipéptido recombinante es una cadena liviana de una inmunoglobulina y dicho segundo polipéptido recombinante es una cadena pesada de una inmunoglobulina. Reivindicación 39: El método acorde con la cláusula 38, donde dicha proteína direccionadora a cuerpos grasos es una proteína A, proteína L o proteína G. Reivindicación 40: El método de la cláusula 21, donde dicha célula es una célula vegetal. Reivindicación 42: Un método para producir en una planta un complejo proteico multimérico recombinante, comprendiendo dicho método los pasos de: a) preparar una primera planta que comprenda células, donde dichas células contienen cuerpos grasos y un primer polipéptido recombinante donde dicho primer polipéptido recombinante tiene la capacidad de asociarse con dichos cuerpos grasos por medio de una proteína direccionadora a cuerpos grasos; b) preparar una segunda planta que comprenda células, donde dichas células contienen cuerpos grasos y un segundo polipéptido recombinante; y c) cruzar sexualmente dicha primera planta con dicha segunda planta con el fin de producir una planta de progenie que comprenda células, donde dichas células contienen cuerpos grasos, donde dichos cuerpos grasos tienen la capacidad de asociarse con dicho primer polipéptido recombinante y dicho primer polipéptido recombinante tiene la capacidad de asociarse con dicho segundo polipéptido recombinante para formar dicho complejo proteico multimérico recombinante. Reivindicación 56: Una secuencia de ácido nucleico quimérica que codifica una proteína de fusión multimérica, comprendiendo dicho ácido nucleico: a) una primera secuencia de ácido nucleico que codifica la proteína direccionadora a cuerpos grasos ligada operativamente en el sentido del marco de lectura con; b) una segunda secuencia de ácido nucleico que codifica al primer polipéptido recombinante; ligada en el sentido del marco de lectura con; c) una tercera secuencia de ácido nucleico que codifica un segundo polipéptido recombinante, donde dicho primer y segundo polipéptido recombinante tienen la capacidad de formar un complejo proteico multimérico. Reivindicación 60: La secuencia de ácido nucleico quimérica de la cláusula 56, donde dicho primer y segundo polipéptido recombinante forman un complejo redox heteromultimérico enzimáticamente activo. Reivindicación 67: Una proteína de fusión multimérica recombinante que comprende (i) una proteína direccionadora a cuerpos grasos, o un fragmento de la misma, (ii) un primer polipéptido recombinante y un (iii) segundo polipéptido recombinante, donde dicho primer y segundo polipéptido recombinante tienen la capacidad de formar un complejo proteico multimérico. Reivindicación 72: El polipéptido de fusión recombinante de la cláusula 71, donde dicho primer polipéptido recombinante es una tioredoxina y dicho segundo polipéptido recombinante es una tioredoxina-reductasa. Reivindicación 78: Cuerpos grasos aislados que comprenden un complejo proteico multimérico, que comprenden (i) una proteína direccionadora a cuerpos grasos y (ii) un primer polipéptido recombinante, donde dichos cuerpos grasos además comprenden un segundo polipéptido recombinante, donde dicho primer y segundo polipéptido recombinante tienen la capacidad de formar un complejo proteico multimérico. Reivindicación 93: Una célula que comprende cuerpos grasos y (i) una proteína direccionadora a cuerpos grasos, (ii) un primer polipéptido recombinante y (iii) un segundo polipéptido recombinante, donde (1) dicho primer polipéptido recombinante tiene la capacidad de asociarse con dicha proteína direccionadora a cuerpos grasos; y (2) dicho primer polipéptido recombinante tiene la capacidad de asociarse con dicho segundo polipéptido recombinante para formar un complejo proteico multimérico. Reivindicación 108: Una planta que comprende las células de la cláusula 93. Reivindicación 116: El método de la cláusula 110, donde dicha composición farmacéutica se usa para el tratamiento de la enfermedad pulmonar obstructiva crónica (COPD), cataratas, diabetes, envenenamiento, enfermedad broncopulmonar, procesos malignos, psoriasis, lesiones por reperfusión, cicatrización de heridas, sepsia, hemorragia GI, enfermedad intestinal inflamatoria (IBD), úlceras, GERD (enfermedad de reflujo gastroesofágico). Reivindicación 117: Una composición que comprende cuerpos grasos aislados, tioredoxina y tioredoxina-reductasa. Reivindicación 121: Un producto alimentario, un producto para el cuidado personal o una composición farmacéutica que comprenden la composición de la cláusula 117. Reivindicación 127: Un método para reducir la alergenicidad de un alimento que comprende los pasos de: proveer los cuerpos grasos aislados de la cláusula 78; y agregar los cuerpos grasos aislados al alimento, con lo cual se reduce la alergenicidad del alimento.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74290000A | 2000-12-19 | 2000-12-19 | |
| US30288501P | 2001-07-05 | 2001-07-05 | |
| US603801A | 2001-12-04 | 2001-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037083A1 true AR037083A1 (es) | 2004-10-20 |
Family
ID=27358025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105914A AR037083A1 (es) | 2000-12-19 | 2001-12-19 | Metodos para la produccion de proteinas redox y complejos proteicos heteromultimericos; composiciones relacionadas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20090197337A1 (es) |
| EP (1) | EP1346056A1 (es) |
| JP (1) | JP4570327B2 (es) |
| KR (1) | KR20030066732A (es) |
| CN (1) | CN100385005C (es) |
| AR (1) | AR037083A1 (es) |
| AU (2) | AU3281902A (es) |
| BR (1) | BR0116220A (es) |
| CA (1) | CA2432315A1 (es) |
| EA (1) | EA009181B1 (es) |
| IL (1) | IL156334A0 (es) |
| MX (1) | MXPA03005548A (es) |
| NZ (1) | NZ526822A (es) |
| TW (1) | TWI317736B (es) |
| WO (1) | WO2002050289A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7009087B1 (en) | 2000-12-01 | 2006-03-07 | Pioneer Hi-Bred International, Inc. | Compositions and methods for altering the disulfide status of proteins |
| CA2447407A1 (en) * | 2001-05-04 | 2002-11-14 | Xencor | Nucleic acids and proteins with thioredoxin reductase activity |
| US20060179514A1 (en) * | 2001-07-05 | 2006-08-10 | Sembiosys Genetics, Inc. | Methods for the production of multimeric protein complexes, and related compositions |
| CA2528741A1 (en) * | 2003-06-17 | 2004-12-23 | Sembiosys Genetics Inc. | Methods for the production of insulin in plants |
| TW200526778A (en) * | 2003-11-14 | 2005-08-16 | Sembiosys Genetics Inc | Methods for the production of apolipoproteins in transgenic plants |
| JP4160615B2 (ja) * | 2004-03-11 | 2008-10-01 | レドックス・バイオサイエンス株式会社 | プロテアーゼ阻害剤 |
| JP2006151861A (ja) * | 2004-11-29 | 2006-06-15 | Redox Bioscience Inc | 喫煙によって引き起こされる臓器障害の予防乃至治療剤 |
| GB0524884D0 (en) * | 2005-12-06 | 2006-01-11 | Syngenta Ltd | Improvements in or relating to organic compounds |
| WO2009009142A2 (en) * | 2007-07-10 | 2009-01-15 | Monsanto Technology, Llc | Transgenic plants with enhanced agronomic traits |
| KR20100135260A (ko) * | 2008-04-11 | 2010-12-24 | 셈바이오시스 제네틱스 인코포레이티드 | 올레오좀으로부터 활성 약제의 방출 조절 |
| ES2354537B1 (es) * | 2008-06-27 | 2012-01-23 | Universidad Pública de Navarra | Tiorredoxinas plastidiales: sobreexpresión y aplicaciones biotecnológicas. |
| ES2384777B1 (es) * | 2008-06-27 | 2013-06-19 | Universidad Pública de Navarra | Tiorredoxinas plastidiales: sobreexpresión y aplicaciones biotecnológicas. |
| TWI377954B (en) * | 2009-11-25 | 2012-12-01 | Univ China Medical | Oil body carriers, uses in target therapy and/or detection of the same, and fusion proteins comprised therein |
| US9745362B2 (en) | 2009-12-09 | 2017-08-29 | Shengjun An | Seed-specific expression vector and its construction methods and applications |
| CN103333915B (zh) * | 2013-07-10 | 2015-08-05 | 吉林农业大学 | 一种含有碱性成纤维细胞生长因子活性多肽的植物油体护肤乳液 |
| CN103343138B (zh) * | 2013-07-10 | 2016-07-13 | 吉林农业大学 | 一种含有酸性成纤维细胞生长因子活性多肽的植物油体护肤乳液 |
| CN103343137B (zh) * | 2013-07-10 | 2015-05-20 | 吉林农业大学 | 一种含有表皮生长因子活性多肽的植物油体护肤乳液 |
| KR101831888B1 (ko) * | 2016-04-15 | 2018-04-16 | (주)케어젠 | 항염증 활성을 갖는 펩타이드 및 이의 용도 |
| CN106905435B (zh) * | 2017-03-13 | 2020-04-10 | 武汉海沙百得生物技术有限公司 | 一种制备基于蛋白a突变体的结合蛋白的方法 |
| CA3069630A1 (en) * | 2017-07-19 | 2019-01-24 | Alcantara Research Group Inc. | Recombinant polypeptide enriched algal chloroplasts, methods for producing the same and uses thereof |
| JP6923166B2 (ja) * | 2019-07-16 | 2021-08-18 | 住友ゴム工業株式会社 | 融合タンパク質、物質製造方法、ベクター、形質転換細胞、空気入りタイヤの製造方法及びゴム製品の製造方法 |
| EP4060045A1 (en) * | 2021-03-16 | 2022-09-21 | Core Biogenesis | A genetically engineered plant or part thereof adapted for the production of recombinant proteins and process thereof |
| CN117500917A (zh) * | 2021-06-23 | 2024-02-02 | 松下知识产权经营株式会社 | 融合蛋白、融合蛋白的制造方法、电极、氧化还原装置、氧化还原方法、二硫键的切断方法和过敏原的灭活方法 |
| AU2022202825B1 (en) * | 2022-04-28 | 2023-09-07 | AUSTRALIAN HEALTH INDUSTRY Co. PTY LTD | Polypeptide, polypeptide composition and application, and prepared anti-wrinkle lotion thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5151350A (en) * | 1982-10-27 | 1992-09-29 | Repligen Corporation | Cloned genes encoding recombinant protein a |
| US4771036A (en) * | 1986-02-10 | 1988-09-13 | Trustees Of Columbia University In The City Of New York | Method and ophthalmic composition for the prevention and reversal of cataracts |
| US4954618A (en) * | 1986-02-14 | 1990-09-04 | Genex Corporation | Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G |
| CA2044296A1 (en) * | 1990-06-12 | 1991-12-13 | Hiroaki Okamoto | Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus |
| US6750046B2 (en) * | 1991-02-22 | 2004-06-15 | Sembiosys Genetics, Inc. | Preparation of thioredoxin and thioredoxin reductase proteins on oil bodies |
| US5948682A (en) * | 1991-02-22 | 1999-09-07 | Sembiosys Genetics Inc. | Preparation of heterologous proteins on oil bodies |
| US6288304B1 (en) * | 1991-02-22 | 2001-09-11 | Sembiosys Genetics Inc. | Expression of somatotropin in plant seeds |
| US7091401B2 (en) * | 1991-02-22 | 2006-08-15 | Sembiosys Genetics Inc. | Expression of epidermal growth factor in plant seeds |
| US5650554A (en) * | 1991-02-22 | 1997-07-22 | Sembiosys Genetics Inc. | Oil-body proteins as carriers of high-value peptides in plants |
| US5792506A (en) * | 1991-10-12 | 1998-08-11 | The Regents Of The University Of California | Neutralization of food allergens by thioredoxin |
| JP3660354B2 (ja) * | 1992-04-02 | 2005-06-15 | セムバイオシス ジェネティクス インコーポレイテッド | 調節シグナルとしてのオイルボディタンパク質シスエレメント |
| SE9201331D0 (sv) * | 1992-04-28 | 1992-04-28 | Hightech Receptor C O Active | Protein l och hybridproteiner daerav |
| US6046037A (en) * | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
| JPH0912471A (ja) * | 1995-06-29 | 1997-01-14 | Noevir Co Ltd | 皮膚外用剤 |
| US5856452A (en) * | 1996-12-16 | 1999-01-05 | Sembiosys Genetics Inc. | Oil bodies and associated proteins as affinity matrices |
| CA2291274C (en) * | 1997-05-27 | 2006-05-16 | Sembiosys Genetics Inc. | Uses of oil bodies |
| US7585645B2 (en) * | 1997-05-27 | 2009-09-08 | Sembiosys Genetics Inc. | Thioredoxin and thioredoxin reductase containing oil body based products |
| US6599513B2 (en) * | 1997-05-27 | 2003-07-29 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| US6183762B1 (en) * | 1997-05-27 | 2001-02-06 | Sembiosys Genetics Inc. | Oil body based personal care products |
| US6761914B2 (en) * | 1997-05-27 | 2004-07-13 | Sembiosys Genetics Inc. | Immunogenic formulations comprising oil bodies |
| US6372234B1 (en) * | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| JP2000103743A (ja) * | 1998-09-29 | 2000-04-11 | Jiyunji Yodoi | チオレドキシン活性を有するファミリーに属するポリペプチド類を含有する食品、化粧品及び医薬 |
| US20060179514A1 (en) * | 2001-07-05 | 2006-08-10 | Sembiosys Genetics, Inc. | Methods for the production of multimeric protein complexes, and related compositions |
| TW200526778A (en) * | 2003-11-14 | 2005-08-16 | Sembiosys Genetics Inc | Methods for the production of apolipoproteins in transgenic plants |
-
2001
- 2001-12-19 MX MXPA03005548A patent/MXPA03005548A/es not_active Application Discontinuation
- 2001-12-19 JP JP2002552166A patent/JP4570327B2/ja not_active Expired - Fee Related
- 2001-12-19 NZ NZ526822A patent/NZ526822A/en unknown
- 2001-12-19 CN CNB018220681A patent/CN100385005C/zh not_active Expired - Fee Related
- 2001-12-19 EP EP01992353A patent/EP1346056A1/en not_active Withdrawn
- 2001-12-19 BR BR0116220-9A patent/BR0116220A/pt not_active IP Right Cessation
- 2001-12-19 AU AU3281902A patent/AU3281902A/xx active Pending
- 2001-12-19 TW TW090131455A patent/TWI317736B/zh not_active IP Right Cessation
- 2001-12-19 EA EA200300708A patent/EA009181B1/ru not_active IP Right Cessation
- 2001-12-19 CA CA002432315A patent/CA2432315A1/en not_active Abandoned
- 2001-12-19 WO PCT/US2001/050240 patent/WO2002050289A1/en active IP Right Grant
- 2001-12-19 US US10/450,903 patent/US20090197337A1/en not_active Abandoned
- 2001-12-19 IL IL15633401A patent/IL156334A0/xx unknown
- 2001-12-19 AR ARP010105914A patent/AR037083A1/es not_active Application Discontinuation
- 2001-12-19 AU AU2002232819A patent/AU2002232819B2/en not_active Ceased
- 2001-12-19 KR KR10-2003-7008298A patent/KR20030066732A/ko active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03005548A (es) | 2004-04-20 |
| BR0116220A (pt) | 2003-09-23 |
| IL156334A0 (en) | 2004-01-04 |
| CN100385005C (zh) | 2008-04-30 |
| EA200300708A1 (ru) | 2003-12-25 |
| WO2002050289A1 (en) | 2002-06-27 |
| WO2002050289A9 (en) | 2003-04-17 |
| EA009181B1 (ru) | 2007-12-28 |
| CN1486368A (zh) | 2004-03-31 |
| JP2004527227A (ja) | 2004-09-09 |
| NZ526822A (en) | 2005-03-24 |
| AU2002232819B2 (en) | 2008-01-03 |
| CA2432315A1 (en) | 2002-06-27 |
| US20090197337A1 (en) | 2009-08-06 |
| WO2002050289A8 (en) | 2005-01-20 |
| JP4570327B2 (ja) | 2010-10-27 |
| KR20030066732A (ko) | 2003-08-09 |
| TWI317736B (en) | 2009-12-01 |
| AU3281902A (en) | 2002-07-01 |
| EP1346056A1 (en) | 2003-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037083A1 (es) | Metodos para la produccion de proteinas redox y complejos proteicos heteromultimericos; composiciones relacionadas | |
| Marquardt et al. | Isolation and characterization of biliprotein aggregates from Acaryochloris marina, a Prochloron‐like prokaryote containing mainly chlorophyll d | |
| Okita et al. | Compartmentation of proteins in the endomembrane system of plant cells | |
| ES2315244T3 (es) | Gelatina recombinante en vacunas. | |
| Bai et al. | A new strategy to produce a defensin: stable production of mutated NP-1 in nitrate reductase-deficient Chlorella ellipsoidea | |
| Emkani et al. | Pea protein extraction assisted by lactic fermentation: Impact on protein profile and thermal properties | |
| Liu et al. | Production of mouse granulocyte‐macrophage colony‐stimulating factor by gateway technology and transgenic rice cell culture | |
| US9637753B2 (en) | In-plant production of oligomeric (comprising three or more units) forms of human Apo A-1 protein muteins | |
| WO2008005847A3 (en) | Method of producing factor viii proteins by recombinant methods | |
| Mainieri et al. | Protein body formation in the endoplasmic reticulum as an evolution of storage protein sorting to vacuoles: insights from maize γ-zein | |
| DE602005023811D1 (de) | Nukleinsäurekonstruct, Expressionsvektor und Verfahren zur Steigerung der Hergestellten Menge von rekombinantem Eiweiss | |
| CN107236759A (zh) | 生菜作为宿主在表达蛋白和/或多肽中的应用 | |
| Cabanos et al. | High-level production of lactostatin, a hypocholesterolemic peptide, in transgenic rice using soybean A1aB1b as carrier | |
| Malavasi et al. | Protein refolding at high pressure: optimization using eGFP as a model | |
| CN106093435B (zh) | 细粒棘球绦虫谷氧还蛋白‑1的应用 | |
| Imbimbo et al. | A cascade extraction of active phycocyanin and fatty acids from Galdieria phlegrea | |
| Scott et al. | Elevation of oil body integrity and emulsion stability by polyoleosins, multiple oleosin units joined in tandem head‐to‐tail fusions | |
| CN101760470B (zh) | 一种制备重组人生长激素的方法 | |
| Yusree et al. | Latest advances in protein-recovery technologies from agricultural waste | |
| Shigemori et al. | Expression of the immunoreactive buckwheat major allergenic storage protein in Lactococcus lactis | |
| Sasou et al. | Development of Antibody-Fragment–Producing Rice for Neutralization of Human Norovirus | |
| JP2011505811A5 (es) | ||
| ES2370683T3 (es) | Procedimiento para producir alergeno de grupo i de acaro recombinante maduro. | |
| TW321686B (es) | ||
| JPS61275229A (ja) | ヒト血清アルブミンの微生物学的調製法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |